MTVA
MetaVia Inc.
$1.74
-13.43%
$9.0M
No data for this timeframe.
Vol
Market Cap$9.0M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders5 funds
Inst. Value$11.6K
SEC Reports8
Recent Activity
Jun 8, 2026
SEC
MetaVia Inc. held its 2026 annual meeting on June 8, 2026, with stockholders approving five proposals including the re-e
8-K — Impact 6/10
Jun 8, 2026
SEC
MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg cohort) at ADA 2026, showing 9.1% mean body weight r
8-K — Impact 6/10
Jun 8, 2026
Insider
Glickman Mark A was granted 17,186 shares
Director
Jun 8, 2026
Insider
KOVEN ANDREW I was granted 17,186 shares
Director
Jun 8, 2026
Insider
GROVES JASON L was granted 17,186 shares
Director
Jun 5, 2026
short_volume
Short Volume: MTVA — 55.6% short (1.3M / 2.3M)
Short: 1,283,891 | Exempt: 21,540 | TRF Vol: 2,307,347 | Short Ratio: 55.6% | Off-exchange volume (d
May 27, 2026
SEC
MetaVia Inc. (MTVA) disclosed Phase 1 data for DA-1726 at EASL 2026. The 48 mg cohort showed up to 9.1% mean body weight
8-K — Impact 6/10
Price Targets
$19.33
+1011.1% upside
Strong Buy
Current $1.74
Low $8.00
Median $20.00
High $30.00
3 analysts
$8.00
$30.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.82 ▲ +2.4% | $-0.87 — $-0.76 | 71% YoY | 3 |
| Next Q | $-0.75 ▲ +20.6% | $-0.96 — $-0.34 | 52% YoY | 3 |
| Current FY | $-2.49 ▼ -1.9% | $-3.69 — $-1.87 | 66% YoY | 3 |
| Next FY | $-2.41 ▼ -1.8% | $-4.61 — $-1.08 | 3% YoY | 3 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD FIDUCIARY TRUST CO | $8.3K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.7K | — |
| BlackRock, Inc. | $575.00 | — |
| DANSKE BANK A/S | $2.00 | — |
| BROWN BROTHERS HARRIMAN & | $2.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Glickman Mark | A | $0.00 |
| Jun 8, 2026 | KOVEN ANDREW | A | $0.00 |
| Jun 8, 2026 | GROVES JASON | A | $0.00 |
| Jun 8, 2026 | Salsbury Michael | A | $0.00 |
| Jun 8, 2026 | STRICKLAND D | A | $0.00 |
5 institutional holders with $11.6K total value (9,645 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 6,940 | $8.3K | 72.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,222 | $2.7K | 23.0% | — |
| 3 | BlackRock, Inc. | 479 | $575.00 | 5.0% | — |
| 4 | DANSKE BANK A/S | 2 | $2.00 | 0.0% | — |
| 5 | BROWN BROTHERS HARRIMAN & CO | 2 | $2.00 | 0.0% | — |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Glickman Mark A | Director | AWARD | 17,186 | — | — |
| Jun 8, 2026 | KOVEN ANDREW I | Director | AWARD | 17,186 | — | — |
| Jun 8, 2026 | GROVES JASON L | Director | AWARD | 17,186 | — | — |
| Jun 8, 2026 | Salsbury Michael | Director | AWARD | 17,186 | — | — |
| Jun 8, 2026 | STRICKLAND D GORDON | Director | AWARD | 17,186 | — | — |
| Jun 8, 2026 | Tursi James Patrick | Director | AWARD | 17,186 | — | — |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.9/10.
MIXED
8-K
6/10
MetaVia Inc. held its 2026 annual meeting on June 8, 2026, with stockholders approving five proposal
Jun 8, 2026
BULLISH
8-K
6/10
MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg cohort) at ADA 2026, showing 9.1
Jun 8, 2026
BULLISH
8-K
6/10
MetaVia Inc. (MTVA) disclosed Phase 1 data for DA-1726 at EASL 2026. The 48 mg cohort showed up to 9
May 27, 2026
NEUTRAL
8-K
4/10
MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic assets DA-1726 (GLP
May 18, 2026
NEUTRAL
8-K
4/10
MetaVia reported Q1 2026 net loss of $3.8M ($0.79/share) vs $3.7M ($3.93/share) in Q1 2025, with cas
May 14, 2026
NEUTRAL
8-K
5/10
MetaVia Inc. announced the first patient dosing in Part 3 of its Phase 1 clinical trial for DA-1726,
Apr 10, 2026
NEUTRAL
EFFECT
5/10
MetaVia Inc.'s registration statement has become effective, enabling the company to proceed with its
Apr 7, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for MetaVi
Mar 18, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.33 mean target
+1011.1% upside
Strong Buy (1.50)
$8.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $1.74 |
| Target Low | $8.00 |
| Target Mean | $19.33 |
| Target Median | $20.00 |
| Target High | $30.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.82 | $-0.87 | $-0.76 | 71.3% | +2.4% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.75 | $-0.96 | $-0.34 | 51.5% | +20.6% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-2.49 | $-3.69 | $-1.87 | 66.2% | -1.9% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-2.41 | $-4.61 | $-1.08 | 3.2% | -1.8% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.820 | |
| 7d ago | $-0.820 | |
| 30d ago | $-0.840 | +0.020 |
| 60d ago | $-0.840 | +0.020 |
| 90d ago | $-1.100 | +0.280 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
09 June 2026 , what are the biggest losers and why ?
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: MTVA — 55.6% short (1.3M / 2.3M)
Short: 1,283,891 | Exempt: 21,540 | TRF Vol: 2,307,347 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: MTVA — 57.7% short (0.3M / 0.5M)
Short: 312,292 | Exempt: 46,397 | TRF Vol: 541,326 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: MTVA — 56.1% short (7.0M / 12.4M)
Short: 6,958,238 | Exempt: 1,058,012 | TRF Vol: 12,394,175 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: MTVA — 56.1% short (10.0M / 17.8M)
Short: 10,004,017 | Exempt: 159,542 | TRF Vol: 17,845,805 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
MTVA Q1 2026 Earnings Scheduled — 2026-05-12
Mar 18, 2026
earnings_calendar
MTVA Q4 2025 Earnings After Market Close — 2026-03-18